SLLN-15 is an orally active, selective, and potent enhancer of autophagy, activating cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1].

Treatment with SLLN-15 at concentrations of 0, 1, 5, 10, and 25 µM for 24 hours significantly decreases the viability of breast cancer cells in a dose-dependent manner, demonstrating its potency against these cells [1]. Similarly, SLLN-15 administered at 100 nM and 1000 nM for 7 days effectively inhibits the colony formation abilities across various breast cancer cell lines, including TNBC (triple-negative breast cancer) lines like MDA-MB-231 and BT-20, without discrimination [1]. SLLN-15 exercises its anti-proliferative effects on TNBC cell lines MDA-MB-231 and BT-20, predominantly through the induction of autophagy and autophagic flux. This action corresponds with a specific inhibition of the AKT-MTOR signaling pathway, further establishing its targeted mechanism in reducing cell viability and proliferation in these cancer cells.

SLLN-15 (30mg/kg, PO, 3 times a week) effectively suppresses triple-negative breast cancer (TNBC) growth and hinders metastasis in animal models, demonstrating significant anti-cancer and anti-metastatic properties. In BALB/c or SCID mice implanted with 1 X 10^6 mouse 4T1 or human MDA-MB-231 cells [1], SLLN-15 markedly slowed tumor growth and reduced lung metastases compared to controls [1].